$EW

BOBO DONALD E JR sold $2.0M of EW (indirect holdings)

BOBO DONALD E JR (CVP,Strategy/Corp Development) sold 23,145 indirectly-held shares of Edwards Lifesciences Corp (EW) at $86.42 ($2.00M total) on 2026-05-27.

Original reporting
SEC EDGAR · BOBO DONALD E JR
Published May 27, 2026, 11:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 11:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EW
Neutral
medium confidence
Mentioned
$EW
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EWNeutralLow
01

Why it matters

Near-term trading impact is likely limited to sentiment/positioning rather than fundamentals, given no accompanying earnings, guidance, trial, or deal information.

02

Market read

A disclosed insider sale can cause brief negative read-through, but without fundamental catalysts it is unlikely to drive a durable repricing.

03

What to watch

The filing notes indirect ownership and does not confirm whether the sale was part of broader planned selling beyond the stated lack of a pre-arranged 10b5-1 plan; also, one Form 4 does not establish a trend.

Relevance 6/10Timing: Same-day/next-session sentiment check; likely limited follow-through.

Background

The article is an SEC Form 4 insider transaction disclosure for Edwards Lifesciences, filed the same day as the sale.

Company-level read

Ticker impact

$EWNeutralMedium confidence
Context

Edwards Lifesciences officer BOBO DONALD E JR sold 23,145 shares in an open-market transaction worth about $2.0M, disclosed via SEC Form 4.

Expected impact

Low probability of sustained price impact; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

Form 4 insider sales are common and often non-informational; absence of a stated 10b5-1 plan can increase interpretation risk, but the filing provides no new company-specific operational or financial information.

Market effects

Minimal; one-off insider sale in a medical device/healthcare name typically does not reset sector expectations.

None indicated; transaction is company-specific and US-listed.

None indicated; no international deal/regulatory/drug-trial content.

Counterpoint

Insider sales frequently reflect diversification, taxes, or routine liquidity needs and may not signal negative fundamentals—especially with a single transaction size.

Key entities

  • Edwards Lifesciences Corp

    Subject of the SEC Form 4 insider sale by an officer (CVP, Strategy/Corp Development).

  • BOBO DONALD E JR

    Officer who executed an open-market sale of 23,145 shares on 2026-05-27.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EWMed

FDA Approves First Heart Valve to Keep Pace With Children's Growth

The FDA approved Edwards Lifesciences' Autus Size-Adjustable Valve, the first heart valve designed to expand with a child's growth, for pediatric patients with congenital pulmonary valve disease. The valve can be implanted at 13 mm and expanded to 22 mm, potentially reducing repeat open-heart surgeries. The approval was based on a pivotal trial with 62 patients, showing acceptable hemodynamic performance and no major complications at 6 months.

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.